| Literature DB >> 30567465 |
Tobias Fehlmann1, Thomas Laufer2,3, Christina Backes1, Mustafa Kahramann1,3, Julia Alles2, Ulrike Fischer2, Marie Minet1,2, Nicole Ludwig2, Fabian Kern1, Tim Kehl4, Valentina Galata1, Aneta Düsterloh3, Hannah Schrörs3, Jochen Kohlhaas3, Robert Bals5, Hanno Huwer6, Lars Geffers7, Rejko Krüger7, Rudi Balling7, Hans-Peter Lenhof4, Eckart Meese2, Andreas Keller1,4.
Abstract
The validation of microRNAs (miRNAs) identified by next generation sequencing involves amplification-free and hybridization-based detection of transcripts as criteria for confirming valid miRNAs. Since respective validation is frequently not performed, miRNA repositories likely still contain a substantial fraction of false positive candidates while true miRNAs are not stored in the repositories yet. Especially if downstream analyses are performed with these candidates (e.g. target or pathway prediction), the results may be misleading. In the present study, we evaluated 558 mature miRNAs from miRBase and 1,709 miRNA candidates from next generation sequencing experiments by amplification-free hybridization and investigated their distributions in patients with various disease conditions. Notably, the most significant miRNAs in diseases are often not contained in the miRBase. However, these candidates are evolutionary highly conserved. From the expression patterns, target gene and pathway analyses and evolutionary conservation analyses, we were able to shed light on the complexity of miRNAs in humans. Our data also highlight that a more thorough validation of miRNAs identified by next generation sequencing is required. The results are available in miRCarta ( https://mircarta.cs.uni-saarland.de ).Entities:
Keywords: MicroRNA validation; NGS; evolution of miRNAs; microarray; northern blot; target pathways
Mesh:
Substances:
Year: 2018 PMID: 30567465 PMCID: PMC6380326 DOI: 10.1080/15476286.2018.1559689
Source DB: PubMed Journal: RNA Biol ISSN: 1547-6286 Impact factor: 4.652